摘要
目的探讨不同分子分型乳腺癌的临床病理特征差异。方法选择乳腺癌患者300例作为研究对象,采用免疫组化法检测Survivin表达情况,同时进行分子分型判定与相关性分析。结果在300例患者中,230例患者Survivin表达阳性,表达阳性率为76.7%。分子分型判断为管腔A型36例,管腔B型180例,HER-2过表达型34例,三阴型50例。不同分子分型患者的病理学分级、淋巴结转移、临床分期、Survivin表达阳性率等对比差异有统计学意义(P<0.05)。多元回归Logistic分析结果显示淋巴结转移、临床分期、Survivin表达阳性是不同分子分型的主要差异(P<0.05)。结论不同分子分型乳腺癌之间具有不同的临床病理学特征,可导致Survivin表达差异。淋巴结转移、临床分期、Survivin表达阳性是不同分子分型的主要差异。
Objective To investigate the correlation between clinicopathological features and molecular typing of breast cancer.Methods 300 patients with breast cancer diagnosed were selected as subjects.The expression of Survivin were detected by immunohistochemistry,and molecular typing and correlation analysis were performed.Results There were 230 patients were positive expression of Survivin in the 300 patients,and the positive rates was 76.7%.Molecular typing were judged as 36 patients of lumen type A,180 patients of lumen type B,34 patients of HER-2 overexpression,and 50 patients of triple negative type.Differences in pathological grade,lymph node metastasis,clinical stage,and Survivin expression positive rate among patients with different molecular types were statistically significant(P<0.05).Multiple regression Logistic analysis showed that lymph node metastasis,clinical stage,and positive Survivin expression were the influencing factors for molecular typing(P<0.05).Conclusion Different molecular types of breast cancer have different clinicopathological characteristics,which could lead to differences in Survivin expression.Lymph node metastasis,clinical stage,and positive Survivin expression are influencing factors for molecular typing.
作者
卜智斌
童真
康锋
BU Zhibin;TONG Zhen;KANG Feng(Weinan Central Hospital,Weinan,714000)
出处
《实用癌症杂志》
2020年第10期1668-1671,共4页
The Practical Journal of Cancer
基金
陕西省卫生健康科研基金项目(编号:2018c007)。
